Video - Results from #40

ASCO GU 2024 VL

Search

Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand Details Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials. With nadofaragene firadenovec's unique once-quarterly dosing schedule...
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George Details Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors and novel hormonal agents for treating metastatic castration-resistant prostate cancer. Dr. George explains the trial's innovative design, which explored the efficacy of abiraterone and olaparib, both separately and in combination, in patient...
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor Details Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...

The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi

April 25, 2024

Details

The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore

April 22, 2024

Details

NePtune Trial: Evaluating Neoadjuvant PARP Inhibition in BRCA-Mutated Prostate Cancer - Rana McKay

March 26, 2024

Details

The STEEL Trial: Evaluating Enzalutamide Plus ADT with Salvage RT for High-Risk Recurrent Prostate Cancer - Edwin Posadas

March 14, 2024

Details

Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston

March 13, 2024

Details

Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce

March 5, 2024

Details

CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George

March 5, 2024

Details

CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir

March 5, 2024

Details

Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore

March 5, 2024

Details

ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer - Andrew Laccetti

March 5, 2024

Details

Intravesical Erdafitinib (TAR-210) Demonstrates High Response Rates in NMIBC With Reduced Toxicity - Roger Li

March 4, 2024

Details

EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden

March 4, 2024

Details

Genetic Overlap Discovered Between Cancerous and Non-Cancerous Bladder Tissue in Small Study - Roger Li

March 4, 2024

Details

ANTICIPATE II Trial: APL-1202 and Tislelizumab for Neoadjuvant Bladder Cancer Treatment - Matthew Galsky

March 4, 2024

Details

Comprehensive Genetic Profiling May Optimize Targeted Therapy Selection for FGFR3-Mutated Urothelial Carcinoma Patients - Michael Basin

March 4, 2024

Details

The Economic Impact of Cystectomy vs Trimodal Bladder Therapy - Stephen Williams

March 1, 2024

Details

Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans

March 1, 2024

Details

Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo

March 1, 2024

Details

Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam

March 1, 2024

Details

The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis

February 29, 2024

Details

Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon

February 29, 2024

Details

Update on Biomarkers in Renal Cell Carcinoma - David Braun

February 29, 2024

Details

LIBERTAS Trial Tests Less Treatment, Better Quality of Life in Responding mHSPC Patients - Arun Azad

February 29, 2024

Details

The De-Escalate Trial: Intermittently Stopping Prostate Cancer Treatments to Improve Quality of Life - Guillaume Grisay

February 28, 2024

Details

Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore

February 28, 2024

Details

BCG Shortage: What’s on the Horizon to Replace? - Joshua Meeks

February 28, 2024

Details

Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta

February 28, 2024

Details

Analyzing Real-World Impact of Race on ADT Mortality in Prostate Cancer - Judd Moul

February 27, 2024

Details

High-Risk Prostate Cancer: 80Gy + ADT Extends Survival Without Added Toxicity - Christophe Hennequin

February 27, 2024

Details

PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik

February 27, 2024

Details

BRCAAWAY Trial: Impact of Abiraterone and Olaparib Combination in Prostate Cancer - Maha Hussain

February 22, 2024

Details

Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer - Peter Goebell

February 22, 2024

Details

Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them? - Chana Weinstock

February 22, 2024

Details

KEYNOTE-564 Shows Overall Survival Benefit in Kidney Cancer with Pembrolizumab - Toni Choueiri

February 21, 2024

Details

CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal

February 21, 2024

Details

Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials - Cheryl Lee

February 21, 2024

Details

Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt

February 20, 2024

Details

Prostate Cancer Foundation's Guidelines for Black Men in the US - Isla Garraway

February 20, 2024

Details

Predicting Recurrence and Monitoring Response in BCG-Unresponsive NMIBC with Urinary Minimal Residual Disease Detection - Vikram Narayan

February 20, 2024

Details

The Efficacy and Resistance-Breaking Potential of EPI-7386 Masofaniten in Castration-Resistant Prostate Cancer - Andrew Laccetti

February 14, 2024

Details

Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand

February 7, 2024

Details

BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George

February 6, 2024

Details

Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor

February 2, 2024

Details